Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13
Excerpt from the Press Release:
SOLANA BEACH, Calif., April 13, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that ART27.13, a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia, shows promising pre-clinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia) via a CB2 mediated mechanism of action.
“These are very encouraging data for two important reasons,” said Richard Porter, Ph.D., of the School of Biochemistry & Immunology at Trinity College Dublin, Ireland. “For the first time, we have evidence that ART27.13 targets a second mechanism of action, the cannabinoid receptor CB2, with these positive pre-clinical results. Furthermore, this mechanism of action extends the potential benefit of ART27.13 to treating cachexia in addition to appetite loss and body weight regulation via CB1 mediated activity.”
“These exciting early results demonstrate that ART27.13 is capable of reducing negative effects of chemicals produced by multiple cancers on human muscle fibers,” added Saoirse O’Sullivan, Ph.D., Vice President Translational Science, Artelo Biosciences. “We look forward to seeing how these results may translate into the ongoing CAReS study currently in the final stages of enrolling cohort 3 at six clinical trial sites in the United Kingdom and Ireland.”
About Cancer-Related Cachexia
Cachexia is a multi-organ, and often irreversible, muscle-wasting syndrome associated with cancer and other serious chronic illnesses. It affects up to 80% of patients with advanced cancer and causes reduced tolerance to cancer therapies, quality of life, and survival rates. Cachexia is an unmet medical need in oncology for which there is no approved therapy.
About ART27.13
ART27.13 is a once-a-day, orally administered, highly potent, peripherally restricted synthetic, dual GPCR agonist believed to target the cannabinoid receptors CB1/CB2, which has the potential to increase appetite, food intake and reduce muscle wasting.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?